DUBLIN, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that its recently FDA-approved InterStim™ Micro neurostimulator for sacral ...
InterStim Therapy is a sacral neuromodulation therapy from Medtronic. InterStim has been regularly used for urinary incontinence for more than a decade, but recently received additional approval as ...
After receiving an FDA approval earlier this week for its newly miniaturized and rechargeable sacral nerve stimulator, Medtronic reported that its first patient has received the implant through the ...
Joseph Welles Henderson, MD, of University Hospitals has been named an InterStim™ Center of Excellence by Medtronic (NYSE: MDT), the world’s largest medical device manufacturer. The designation is ...
announced today that newly published data from a multicenter, prospective trial show that sacral nerve stimulation using Medtronic InterStim® Therapy reduced incontinent episodes and increased quality ...
Medtronic and Axonics have been going toe-to-toe in sacral neuromodulation — a fast-growing market that was monopolized by Medtronic until September 2019 — and the incumbent may have just gained the ...
Medtronic plc has won U.S. FDA approval of its Interstim Micro rechargeable sacral nerve stimulator and Interstim Surescan MRI leads for the treatment of urinary and bowel dysfunctions. The new ...
Medtronic continues to up its game in sacral neuromodulation. FDA approved InterStim X, the next generation of the company's InterStim portfolio's recharge-free device. Medtronic said implants have ...
The FDA has approved an app-based smart programming device used to discreetly and easily control implants treating for overactive bladder (OAB), chronic fecal incontinence (FI) and non-obstructive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results